Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2016 - 2020)

Historic Non-Current Deffered Revenue for Ptc Therapeutics (PTCT) over the last 7 years, with Q1 2020 value amounting to $1.8 million.

  • Ptc Therapeutics' Non-Current Deffered Revenue fell 8002.94% to $1.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.8 million, marking a year-over-year decrease of 8002.94%. This contributed to the annual value of $3.4 million for FY2019, which is 6487.35% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Non-Current Deffered Revenue of $1.8 million as of Q1 2020, which was down 8002.94% from $3.4 million recorded in Q4 2019.
  • Ptc Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $11.2 million during Q3 2018, with a 5-year trough of $1.6 million in Q4 2016.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $7.2 million (2017), whereas its average is $6.4 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Non-Current Deffered Revenue soared by 40119.72% in 2017, and later plummeted by 8002.94% in 2020.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Non-Current Deffered Revenue stood at $1.6 million in 2016, then surged by 401.2% to $8.0 million in 2017, then rose by 22.23% to $9.7 million in 2018, then crashed by 64.87% to $3.4 million in 2019, then crashed by 48.23% to $1.8 million in 2020.
  • Its last three reported values are $1.8 million in Q1 2020, $3.4 million for Q4 2019, and $5.5 million during Q3 2019.